Ginai et al for IR.pdf (697.26 kB)
The use of bioreactors as in vitro models in pharmaceutical research
journal contribution
posted on 2014-03-06, 11:17 authored by Maaria Ginai, Robert Elsby, Christopher Hewitt, Dominic Surry, Katherine Fenner, Karen CoopmanKaren CoopmanBringing a new drug to market is costly in terms of capital and time investments, and any development issues encountered during late-stage clinical trials can often be the result of in vitro-in vivo extrapolations (IVIVE) not accurately reflecting clinical outcome. In the discipline of drug metabolism and pharmacokinetics (DMPK), current in vitro cellular methods do not provide the 3D structure and function of organs found in vivo; therefore, new dynamic methods need to be established to aid improvement of IVIVE. In this review, we highlight the importance of model progression into dynamic systems for use within drug development, focusing on devices developed currently in the areas of the liver and blood-brain barrier (BBB), and the potential to develop models for other organ systems, such as the kidney. We discuss the development of dynamic 3D bioreactor-based systems as in vitro models for use in DMPK studies.
History
School
- Aeronautical, Automotive, Chemical and Materials Engineering
Department
- Chemical Engineering
Citation
GINAI, M. ... et al., 2013. The use of bioreactors as in vitro models in pharmaceutical research. Drug Discovery Today, 18 (19-20), pp. 922 - 935.Publisher
© Elsevier Ltd.Version
- SMUR (Submitted Manuscript Under Review)
Publication date
2013Notes
This article was published in the journal, Drug Discovery Today [© Elsevier Ltd.] and the definitive version is available at: http://dx.doi.org/10.1016/j.drudis.2013.05.016ISSN
1359-6446eISSN
1878-5832Publisher version
Language
- en